HK1258326A1 - 穩定地含有抑制TGF-β1基因的表達的單鏈核酸分子的組合物 - Google Patents

穩定地含有抑制TGF-β1基因的表達的單鏈核酸分子的組合物

Info

Publication number
HK1258326A1
HK1258326A1 HK19100694.8A HK19100694A HK1258326A1 HK 1258326 A1 HK1258326 A1 HK 1258326A1 HK 19100694 A HK19100694 A HK 19100694A HK 1258326 A1 HK1258326 A1 HK 1258326A1
Authority
HK
Hong Kong
Prior art keywords
tgf
nucleic acid
acid molecule
stranded nucleic
containing single
Prior art date
Application number
HK19100694.8A
Other languages
English (en)
Inventor
山田太務
豐福秀一
田原耕平
小野寺理沙子
竹內洋文
Original Assignee
株式會社博納克
竹内洋文
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式會社博納克, 竹内洋文 filed Critical 株式會社博納克
Publication of HK1258326A1 publication Critical patent/HK1258326A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK19100694.8A 2015-10-30 2019-01-16 穩定地含有抑制TGF-β1基因的表達的單鏈核酸分子的組合物 HK1258326A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015215207 2015-10-30
PCT/JP2016/082164 WO2017073767A1 (ja) 2015-10-30 2016-10-28 TGF-β1遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物

Publications (1)

Publication Number Publication Date
HK1258326A1 true HK1258326A1 (zh) 2019-11-08

Family

ID=58631737

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100694.8A HK1258326A1 (zh) 2015-10-30 2019-01-16 穩定地含有抑制TGF-β1基因的表達的單鏈核酸分子的組合物

Country Status (15)

Country Link
US (1) US10751426B2 (zh)
EP (1) EP3369816B1 (zh)
JP (1) JP6609637B2 (zh)
KR (1) KR102099711B1 (zh)
CN (1) CN108350457B (zh)
AU (1) AU2016346703B2 (zh)
BR (1) BR112018008613A2 (zh)
CA (1) CA3002786C (zh)
HK (1) HK1258326A1 (zh)
IL (1) IL258861B (zh)
MX (1) MX2018005146A (zh)
PL (1) PL3369816T3 (zh)
RU (1) RU2714257C2 (zh)
SG (1) SG11201803410RA (zh)
WO (1) WO2017073767A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
RU2020130258A (ru) * 2018-03-30 2022-05-04 Торэй Индастриз, Инк. Способ получения шпилечной одноцепочечной молекулы рнк
EP3862431B1 (en) * 2018-10-02 2024-06-26 Toray Industries, Inc. Method for producing hairpin single-strand rna molecules

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219445B (hu) * 1992-09-17 2001-04-28 Amgen Inc. Interleukin-1 inhibitorokat tartalmazó, stabil gyógyszerkészítmények és eljárás előállításukra
JP4956727B2 (ja) * 2005-08-30 2012-06-20 倉敷紡績株式会社 Rna分離精製方法
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd RNA干擾(RNAi)所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用(二)
AU2007304776A1 (en) * 2006-10-06 2008-04-10 Dna Genotek Inc. Stabilizing compositions and methods for extraction of ribonucleic acid
EP2224912B1 (en) * 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
JP5608998B2 (ja) * 2009-03-31 2014-10-22 東洋紡株式会社 保存安定性に優れた核酸増幅検出試薬キット
ES2594365T3 (es) * 2010-02-12 2016-12-19 Intas Pharmaceuticals Ltd. Formulación líquida de hormona estimulante del folículo
EP2550002B1 (en) * 2010-03-24 2019-05-08 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
HUE037500T2 (hu) 2010-07-08 2018-08-28 Bonac Corp Egyszálú nukleinsav molekula a génexpresszió szabályozására
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
PT2674494E (pt) 2010-08-03 2015-02-27 Bonac Corp Molécula de arn em cadeia simples com esqueleto licíclico contendo azoto
SG187697A1 (en) 2010-08-16 2013-03-28 Australian Nuclear Science Tec Particulate substances comprising ceramic particles for delivery of biomolecules
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
JP2014500867A (ja) * 2010-11-09 2014-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚浸透性および細胞侵入性(space)ペプチドとその使用法
JP5854595B2 (ja) 2010-12-07 2016-02-09 株式会社Shoei ヘルメット用ラチェットバックル
WO2013077446A1 (ja) 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
EP2801617B1 (en) * 2012-01-07 2017-09-06 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
WO2013133393A1 (ja) 2012-03-07 2013-09-12 学校法人東京医科大学 Vegf遺伝子の発現抑制用一本鎖核酸分子
CA2867888C (en) 2012-03-21 2021-06-01 Engene, Inc. Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
WO2014059430A1 (en) * 2012-10-14 2014-04-17 Board Of Regents, The University Of Texas System Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscalle hydrogels
CN102895190A (zh) * 2012-10-16 2013-01-30 百奥迈科生物技术有限公司 脂质体制剂、制备方法及其应用
AU2013380825B2 (en) * 2012-10-16 2017-07-20 Biomics Biotechnologies Co., Ltd. Lipidosome preparation, preparation method and application thereof
CN105051064A (zh) 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック TGF-β1遺伝子発現制御のための一本鎖核酸分子
SG10201913570XA (en) * 2013-12-27 2020-03-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
JP6462723B2 (ja) * 2014-12-29 2019-01-30 株式会社ボナック 核酸分子を安定に含有する組成物

Also Published As

Publication number Publication date
CN108350457A (zh) 2018-07-31
AU2016346703B2 (en) 2020-07-02
RU2714257C2 (ru) 2020-02-13
KR102099711B1 (ko) 2020-04-14
KR20180066250A (ko) 2018-06-18
WO2017073767A1 (ja) 2017-05-04
CN108350457B (zh) 2021-10-01
US10751426B2 (en) 2020-08-25
EP3369816A4 (en) 2019-06-26
MX2018005146A (es) 2018-08-23
RU2018119672A3 (zh) 2019-12-02
EP3369816B1 (en) 2024-03-13
EP3369816A1 (en) 2018-09-05
PL3369816T3 (pl) 2024-07-22
IL258861A (en) 2018-06-28
BR112018008613A2 (pt) 2018-10-30
JP6609637B2 (ja) 2019-11-20
AU2016346703A1 (en) 2018-06-21
US20180339064A1 (en) 2018-11-29
CA3002786A1 (en) 2017-05-04
SG11201803410RA (en) 2018-05-30
IL258861B (en) 2021-12-01
RU2018119672A (ru) 2019-12-02
JPWO2017073767A1 (ja) 2018-10-04
CA3002786C (en) 2021-09-07

Similar Documents

Publication Publication Date Title
IL294192B1 (en) Sequencing a single molecule of DNA. plasma
HUE052552T2 (hu) Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz
EP3365446A4 (en) SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
IL252556A0 (en) Nucleic acid constructs for genome editing
IL256905A (en) Methods for Amplifying Nucleic Acid Sequences
IL249619A0 (en) Analysis of nucleic acid sequences
LT3337902T (lt) 3` utr sekos, skirtos rnr stabilizavimui
MX2016011538A (es) Acidos nucleicos antisentido.
EP2857513A4 (en) SINGLE STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING THE EXPRESSION OF A GENE HAVING AN ADMINISTRATION FUNCTION
HK1244030A1 (zh) 穩定含有核酸分子的組合物
HK1244031A1 (zh) 具有遞送功能和基因表達調控能力的單鏈核酸分子
EP3323893A4 (en) BETA2GPI GENE EXPRESSION-INHIBITING NUCLEIC ACID COMPLEX
SG10201912967YA (en) Determination of nucleic acid methylation
HK1259060A1 (zh) 抑制腎素原基因或腎素原受體基因表達的單鏈核酸分子及其用途
HK1258326A1 (zh) 穩定地含有抑制TGF-β1基因的表達的單鏈核酸分子的組合物
HK1252259A1 (zh) 用於使時鐘基因的表達變化的組合物
DK3325621T3 (da) Kloning af en-strenget nucleinsyre
EP2774989A4 (en) DOUBLE-STRUCTURED NUCLEIC ACID MOLECULE FOR GENE EXPRESSION CONTROL
HK1231403A1 (zh) 抑制β 表達的核酸
HK1251235A1 (zh) 由輔助寡核苷酸物質對核酸雜交探針的化學計量調節
EP3631006A4 (en) DNA STABILIZATION OF RNA
IL255081B (en) Identification of nucleic acid molecules
EP3351251A4 (en) NUCLEIC ACID MOLECULE
HK1244035A1 (zh) 用於抑制TGF-β1表達的單鏈核酸分子
EP3696270A4 (en) REGULATION OF THE EXPRESSION OF NUCLEIC ACID MOLECULES